admin

Social media is no longer just a numbers game for pharma companies. Counting followers, tallying likes or tracking shares was a good start, but numbers alone can’t tell if business goals are met.

That’s especially true in the current era of paid promotions, where numbers can be artificially inflated. Pharma companies today need to figure out how social media helps them reach the right influencers and key opinion leaders, drive traffic to websites or change perceptions of the products or company.

Emergent Biosolutions CEO Robert Kramer told CNBC Monday it is uncertain that a coronavirus vaccine can be available by the end of the year to fulfill President Donald Trump’s wishes.

The specialty biopharmaceutical company is collaborating with drug giant Johnson & Johnson on a Covid-19 vaccine candidate, which Johnson & Johnson hopes will receive emergency use authorization in 2021.

ROCKVILLE, Md.–(BUSINESS WIRE)–May 5, 2020–

Immunomic Therapeutics, Inc., (“ITI”) a privately-held clinical-stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today the appointment of five new members to its Board of Directors from HLB, Co. Ltd (“HLB”) and its HLB Bio subsidiaries.

“I am delighted to welcome the new members from HLB to our board as they bring exceptional scientific, operational and commercial expertise to the group,” said Dr. William Hearl, CEO of Immunomic Therapeutics. “As we advance our UNITE platform and our efforts in immune-oncology, their expertise and successful track record in bringing novel oncology drugs to market will be invaluable to our team.”

Since the enactment of the CARES Act, the Small Business Administration and U.S. Department of the Treasury have continually updated the rules governing the Paycheck Protection Program (PPP) through formal rulemaking and less formal guidance. Join a team of Venable Financial Services and Corporate partners for a discussion around guidance for preparing for an audit (and potential investigation). Our discussion will include best practices for documenting decision making, what we can expect from the SBA going forward, and how best to manage an audit and address any potential investigation.

He joins BioTalk host Rich Bendis to discuss their recent successes in funding, research, and their growth in the BioHealth Capital Region

Dr. William Hearl is the founder of Immunomic Therapeutics, Inc. and is an experienced and successful life science businessman and entrepreneur. Dr. Hearl is adept at brokering mutually beneficial partnerships and identifying non-traditional collaborations and investment opportunities.

The advent of the commercial development of LAMP technology came from discussions between Dr. Hearl and Dr. Tom August at Johns Hopkins University. Based on their mutual vision of the value of LAMP, ITI emerged and began operations in 2006. Dr. Hearl’s extensive experience in intellectual property management and business development led to the reward of a sub-license of the LAMP technology to Geron Corporation within 30 days of initiating operations and subsequent license agreements, valued at over $300 million, in 2015 with Japan-based Astellas for next generation allergy vaccines based on the LAMP platform.

I know what you’re thinking…it’s hard enough to raise venture capital for life science/healthcare startups in normal times, but throw a global pandemic and economic meltdown into the mix and even the best-laid plans will certainly go astray! So here are the questions that entrepreneurs would like answers to: Is there an inevitable slowdown in venture financing? How can VC firms conduct due diligence efficiently and thoroughly during a lockdown? Is a videoconference enough to establish a trusting relationship with a CEO and a Board? Does every startup have to take a hit on valuation if they want to get funding? Has the Coronavirus fundamentally changed expectations, time horizons, governance, and risk tolerance? What’s it gonna take to get someone to write a check?

I know what you’re thinking…it’s hard enough to raise venture capital for life science/healthcare startups in normal times, but throw a global pandemic and economic meltdown into the mix and even the best-laid plans will certainly go astray! So here are the questions that entrepreneurs would like answers to: Is there an inevitable slowdown in venture financing? How can VC firms conduct due diligence efficiently and thoroughly during a lockdown? Is a videoconference enough to establish a trusting relationship with a CEO and a Board? Does every startup have to take a hit on valuation if they want to get funding? Has the Coronavirus fundamentally changed expectations, time horizons, governance, and risk tolerance? What’s it gonna take to get someone to write a check?